1.
PDF
Newman-Matthew-OHSU-ResearchWeek-2022
Early phospho-signaling shifts in Smart BufferTM-preserved peripheral blood specimens in response to FLT3 inhibitor therapy
Newman, Matthew T. ; Baker, Kristina ; Joshi, Sunil K. ; Pittsenbarger, Janet[...]
Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]
2022 | Abstract |
Detailed record - Similar records
2.
PDF
Sharzehi-Setareh-OHSU-ResearchWeek-2022
The FLT3 F691L gatekeeper mutation promotes clinical resistance to Gilteritinib + Venetoclax in AML
Sharzehi, Setareh ; Joshi, Sunil ; Pittsenbarger, Janet ; Bottomly, Daniel[...]
Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated gene [...]
2022 | Abstract |
Detailed record - Similar records